Jefferies Starts Opko Health (OPK) at Buy

Jefferies initiates coverage on Opko Health (NYSE: OPK) with a Buy rating and $8 price target.

The firm comments, "OPK is not a typical biotech/healthcare company, rather it is a holding company with constantly evolving investment in product/technology for risk diversification and growth enhancement. While unquantifiable value of OPK shares lies in Dr. Phillip Frost's track record (CEO at OPK, chairman of board at TEVA), we view its diversified portfolio as attractive for significant upside opportunities at limited downside risks."

For an analyst ratings summary and ratings history on Opko Health click here. For more ratings news on Opko Health click here.

Shares of Opko Health closed at $5.11 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Jefferies Upgrades Arteris, Inc (AIP) to Buy
• JPMorgan Resumes Resideo Technologies (REZI) at Neutral
• Citi Starts Lingyi Itech Guangdong Co (002600:CH) at Buy